|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US5132405A
(en)
|
1987-05-21 |
1992-07-21 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US5091513A
(en)
|
1987-05-21 |
1992-02-25 |
Creative Biomolecules, Inc. |
Biosynthetic antibody binding sites
|
|
US6765087B1
(en)
|
1992-08-21 |
2004-07-20 |
Vrije Universiteit Brussel |
Immunoglobulins devoid of light chains
|
|
ES2156149T3
(es)
|
1992-12-04 |
2001-06-16 |
Medical Res Council |
Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
|
|
ES2162863T3
(es)
|
1993-04-29 |
2002-01-16 |
Unilever Nv |
Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
|
|
US5464758A
(en)
|
1993-06-14 |
1995-11-07 |
Gossen; Manfred |
Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters
|
|
US5814618A
(en)
|
1993-06-14 |
1998-09-29 |
Basf Aktiengesellschaft |
Methods for regulating gene expression
|
|
UA76934C2
(en)
|
1996-10-04 |
2006-10-16 |
Chugai Pharmaceutical Co Ltd |
Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
|
|
US6986890B1
(en)
|
1996-11-21 |
2006-01-17 |
Kyowa Hakko Kogyo Co., Ltd. |
Anti-human VEGF receptor Flt-1 monoclonal antibody
|
|
US6428965B1
(en)
|
1997-07-17 |
2002-08-06 |
The Johns Hopkins University |
Screening assays for the interaction of semaphorins and neuropilins
|
|
DE19742706B4
(de)
|
1997-09-26 |
2013-07-25 |
Pieris Proteolab Ag |
Lipocalinmuteine
|
|
CA2313607A1
(en)
|
1997-12-09 |
1999-06-17 |
Children's Medical Center Corporation |
Antagonists of neuropilin receptor function and use thereof
|
|
EP1037981A1
(en)
|
1997-12-09 |
2000-09-27 |
Children's Medical Center Corporation |
Soluble inhibitors of vascular endothelial growth factor and use thereof
|
|
CA2313390A1
(en)
|
1997-12-09 |
1999-06-17 |
Children's Medical Center Corporation |
Peptide antagonists of vascular endothelial growth factor
|
|
FR2775435B1
(fr)
|
1998-02-27 |
2000-05-26 |
Bioalliance Pharma |
Nanoparticules comprenant au moins un polymere et au moins un compose apte a complexer un ou plusieurs principes actifs
|
|
AUPP221098A0
(en)
|
1998-03-06 |
1998-04-02 |
Diatech Pty Ltd |
V-like domain binding molecules
|
|
EP1117720A4
(en)
|
1998-07-13 |
2001-11-14 |
Expression Genetics Inc |
POLYESTER POLY-L-LYSINE ANALOG USED AS A BIODEGRADABLE SOLUBLE GENE CONVEYOR
|
|
WO2000029447A1
(en)
|
1998-11-19 |
2000-05-25 |
Smithkline Beecham Corporation |
Rhamm antagonist antibodies
|
|
US6210922B1
(en)
|
1998-11-30 |
2001-04-03 |
National Research Council Of Canada |
Serum free production of recombinant proteins and adenoviral vectors
|
|
US7115396B2
(en)
|
1998-12-10 |
2006-10-03 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6387620B1
(en)
|
1999-07-28 |
2002-05-14 |
Gilead Sciences, Inc. |
Transcription-free selex
|
|
US20040038339A1
(en)
|
2000-03-24 |
2004-02-26 |
Peter Kufer |
Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
|
|
AU2001289284A1
(en)
|
2000-04-04 |
2001-10-15 |
Enanta Pharmaceuticals, Inc. |
Methods for identifying peptide aptamers capable of altering a cell phenotype
|
|
ES2252261T3
(es)
|
2000-06-28 |
2006-05-16 |
Glycofi, Inc. |
Metodos para producir glicoproteinas modificadas.
|
|
EP1332209B1
(en)
|
2000-09-08 |
2009-11-11 |
Universität Zürich |
Collections of repeat proteins comprising repeat modules
|
|
US6376190B1
(en)
|
2000-09-22 |
2002-04-23 |
Somalogic, Inc. |
Modified SELEX processes without purified protein
|
|
FR2814642B1
(fr)
|
2000-10-03 |
2005-07-01 |
Ass Pour Le Dev De La Rech En |
Souris transgenique pour la recombinaison ciblee mediee par la cre-er modifiee
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
|
US7183388B2
(en)
|
2001-03-30 |
2007-02-27 |
The Regents Of The University Of California |
Anti-MUC-1 single chain antibodies for tumor targeting
|
|
US20030082630A1
(en)
|
2001-04-26 |
2003-05-01 |
Maxygen, Inc. |
Combinatorial libraries of monomer domains
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20050089932A1
(en)
|
2001-04-26 |
2005-04-28 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
US6900292B2
(en)
|
2001-08-17 |
2005-05-31 |
Lee-Hwei K. Sun |
Fc fusion proteins of human erythropoietin with increased biological activities
|
|
JP4213586B2
(ja)
|
2001-09-13 |
2009-01-21 |
株式会社抗体研究所 |
ラクダ抗体ライブラリーの作製方法
|
|
US20040214766A1
(en)
*
|
2001-10-01 |
2004-10-28 |
Kari Alitalo |
VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
|
|
US20030113324A1
(en)
|
2001-10-01 |
2003-06-19 |
Kari Alitalo |
Neuropilin/VEGF-C/VEGFR-3 materials and methods
|
|
CA2463879C
(en)
|
2001-10-25 |
2012-12-04 |
Genentech, Inc. |
Glycoprotein compositions
|
|
US7662925B2
(en)
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
|
US7244592B2
(en)
|
2002-03-07 |
2007-07-17 |
Dyax Corp. |
Ligand screening and discovery
|
|
CA2481658A1
(en)
|
2002-04-09 |
2003-10-16 |
Kyowa Hakko Kogyo Co., Ltd. |
Method of enhancing of binding activity of antibody composition to fcy receptor iiia
|
|
ATE525398T1
(de)
|
2002-05-10 |
2011-10-15 |
Medimmune Inc |
Epha2 monoklonale antikörper und deren anwendungsverfahren
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
ATE408398T1
(de)
|
2002-07-29 |
2008-10-15 |
Nanodel Technologies Gmbh |
Nanopartikele für dna verabreichung zu einem zielorgan
|
|
US20090017023A1
(en)
|
2002-08-14 |
2009-01-15 |
Macrogenics, Inc. |
FcGammaRIIB Specific Antibodies and Methods of Use Thereof
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
WO2004035537A2
(en)
|
2002-10-16 |
2004-04-29 |
Euro-Celtique S.A. |
Antibodies that bind cell-associated ca 125/o772p and methods of use thereof
|
|
UA89348C2
(ru)
*
|
2002-10-16 |
2010-01-25 |
Евро-Селтик С.А. |
Изолированное моноклональное антитело, которое связывает клеточно-ассоциированный полипептид са 125/о772р
|
|
US7727969B2
(en)
|
2003-06-06 |
2010-06-01 |
Massachusetts Institute Of Technology |
Controlled release nanoparticle having bound oligonucleotide for targeted delivery
|
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
|
WO2005037867A1
(en)
|
2003-10-15 |
2005-04-28 |
Pdl Biopharma, Inc. |
ALTERATION OF Fc-FUSION PROTEIN SERUM HALF-LIVES BY MUTAGENESIS OF POSITIONS 250, 314 AND/OR 428 OF THE HEAVY CHAIN CONSTANT REGION OF IG
|
|
US9296820B2
(en)
|
2003-11-05 |
2016-03-29 |
Roche Glycart Ag |
Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
|
|
WO2005063815A2
(en)
|
2003-11-12 |
2005-07-14 |
Biogen Idec Ma Inc. |
Fcϝ receptor-binding polypeptide variants and methods related thereto
|
|
ES2383300T3
(es)
|
2003-11-13 |
2012-06-20 |
Hanmi Holdings Co., Ltd |
Fragmento Fc de IgG para un vehículo de fármacos y procedimiento para su preparación
|
|
US7982011B2
(en)
|
2003-11-25 |
2011-07-19 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Mutated anti-cd22 antibodies and immunoconjugates
|
|
US20080220049A1
(en)
|
2003-12-05 |
2008-09-11 |
Adnexus, A Bristol-Myers Squibb R&D Company |
Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
|
|
CN101426489A
(zh)
|
2004-04-16 |
2009-05-06 |
曹义海 |
抑制血管生成的成分和方法
|
|
AU2005274905B2
(en)
|
2004-08-04 |
2010-12-23 |
Mentrik Biotech, Llc |
Variant Fc regions
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US7459529B2
(en)
|
2004-11-24 |
2008-12-02 |
Seoul National University Industry Foundation |
AIMP2-DX2 and its uses
|
|
US20090196850A1
(en)
|
2005-01-06 |
2009-08-06 |
Novo Nordisk A/S |
Anti-Kir Combination Treatments and Methods
|
|
AU2005325801A1
(en)
|
2005-01-31 |
2006-08-03 |
Ablynx N.V. |
Method for generating variable domain sequences of heavy chain antibodies
|
|
US7404969B2
(en)
|
2005-02-14 |
2008-07-29 |
Sirna Therapeutics, Inc. |
Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
BRPI0611445A2
(pt)
|
2005-05-09 |
2010-09-08 |
Glycart Biotechnology Ag |
molécula de ligação a antìgeno glicomanipulada, polinucleotìdeo, polipeptìdeo, vetor, célula hospedeira, método para produção, uso e composição farmacêutica
|
|
EP1739092A1
(en)
|
2005-06-28 |
2007-01-03 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Peptidic antagonists of class III semaphorins/neuropilins complexes
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
WO2007011896A2
(en)
|
2005-07-18 |
2007-01-25 |
The Trustees Of Boston University |
Method to inhibit proliferation and growth of metastases
|
|
WO2007020075A1
(en)
|
2005-08-16 |
2007-02-22 |
Klinikum Der Universität Regensburg |
Use of neuropilin-2 antagonists
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
SI1945665T1
(sl)
|
2005-10-21 |
2012-03-30 |
Genzyme Corp |
Terapevtska sredstva na osnovi protiteles s povečano ADCC aktivnostjo
|
|
US20080206246A1
(en)
|
2006-04-05 |
2008-08-28 |
Ravetch Jeffrey V |
Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
|
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
|
CA2631184A1
(en)
|
2005-11-28 |
2007-05-31 |
Genmab A/S |
Recombinant monovalent antibodies and methods for production thereof
|
|
US7420040B2
(en)
|
2006-02-24 |
2008-09-02 |
Arius Research Inc. |
Cytotoxicity mediation of cells evidencing surface expression of TROP-2
|
|
EP2011870A4
(en)
|
2006-04-14 |
2010-09-15 |
Medical & Biol Lab Co Ltd |
MUTANT POLYPEPTIDE WITH EFFECTOR FUNCTION
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
WO2008114011A2
(en)
|
2007-03-19 |
2008-09-25 |
Medimmune Limited |
Fc polypeptide variants obtained by ribosome display methodology
|
|
EP2162552A4
(en)
|
2007-05-11 |
2010-06-30 |
Univ Johns Hopkins |
BIOMARKER FOR MELANOME
|
|
JP5745840B2
(ja)
|
2007-05-17 |
2015-07-08 |
ジェネンテック， インコーポレイテッド |
抗ニューロピリン２抗体による腫瘍転移の阻害
|
|
KR101523788B1
(ko)
|
2007-05-17 |
2015-06-26 |
제넨테크, 인크. |
뉴로필린 단편 및 뉴로필린-항체 복합체의 결정 구조
|
|
ES2623925T3
(es)
|
2007-05-30 |
2017-07-12 |
Postech Academy-Industry- Foundation |
Proteínas de fusión de inmunoglobulina
|
|
CN101970012A
(zh)
|
2007-09-14 |
2011-02-09 |
日东电工株式会社 |
药物载体
|
|
WO2009097017A2
(en)
|
2007-09-18 |
2009-08-06 |
The Jackson Laboratory |
Antibodies and fc fusion protein modifications with enhanced persistence or pharmacokinetic stability in vivo and methods of use thereof
|
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
|
FR2935385B1
(fr)
|
2008-08-27 |
2013-04-19 |
Diaclone |
Induction de l'expression de p53 par neutralisation de la neuropiline-2 pour le traitement des cancers
|
|
US9181342B2
(en)
|
2008-09-12 |
2015-11-10 |
Isis Innovation Limited |
PD-1 specific antibodies and uses thereof
|
|
US8552154B2
(en)
|
2008-09-26 |
2013-10-08 |
Emory University |
Anti-PD-L1 antibodies and uses therefor
|
|
PT2374883T
(pt)
|
2008-12-26 |
2016-10-20 |
Kyowa Hakko Kirin Co Ltd |
Anticorpo anti-cd4
|
|
JP5844159B2
(ja)
|
2009-02-09 |
2016-01-13 |
ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ |
Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
|
|
TWI541021B
(zh)
|
2009-03-05 |
2016-07-11 |
艾伯維有限公司 |
Ｉｌ－１７結合蛋白
|
|
CN102459335B
(zh)
|
2009-04-17 |
2015-11-25 |
伊缪纳斯制药株式会社 |
特异性结合Aβ寡聚体的抗体及其用途
|
|
RU2012114094A
(ru)
|
2009-09-11 |
2013-10-20 |
Дженентек, Инк. |
Способ идентификации пациента с увеличенной вероятностью ответа на противораковый агент
|
|
KR20120089863A
(ko)
|
2009-10-09 |
2012-08-14 |
사노피 |
“개선된 당화반응 최종 생성물에 대한 수용체”에 결합하기 위한 폴리펩타이드 및 이를 포함하는 조성물 및 방법
|
|
EP2488874A4
(en)
|
2009-10-13 |
2013-08-14 |
Univ Johns Hopkins |
BIOMARKERS FOR THE IDENTIFICATION OF MELANOMOTUM CELLS
|
|
EP2496268A4
(en)
|
2009-11-06 |
2013-06-19 |
Univ Chung Ang Ind |
GENERATING SYSTEMS ON NANOPARTICLE BASIS
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
EP2545078A1
(en)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1 antibody
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
HUE049849T2
(hu)
|
2010-03-31 |
2020-10-28 |
Boehringer Ingelheim Int |
Anti-CD40 antitestek
|
|
KR101209266B1
(ko)
|
2010-06-30 |
2012-12-06 |
한국과학기술연구원 |
생분해성 및 온도 감응성 폴리포스파젠계 자성 고분자, 그의 제조 방법 및 용도
|
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
|
US9243057B2
(en)
|
2010-08-31 |
2016-01-26 |
The Regents Of The University Of California |
Antibodies for botulinum neurotoxins
|
|
AU2011333738A1
(en)
|
2010-11-24 |
2013-07-11 |
Glaxo Group Limited |
Multispecific antigen binding proteins targeting HGF
|
|
KR101308591B1
(ko)
|
2010-12-30 |
2013-09-13 |
주식회사 삼양바이오팜 |
양이온성 지질을 포함하는 음이온성 약물 전달체 및 그 제조방법
|
|
WO2012144208A1
(ja)
|
2011-04-18 |
2012-10-26 |
国立大学法人東京大学 |
抗itm2a抗体を用いる癌の診断および治療
|
|
US8691750B2
(en)
|
2011-05-17 |
2014-04-08 |
Axolabs Gmbh |
Lipids and compositions for intracellular delivery of biologically active compounds
|
|
KR101383324B1
(ko)
|
2011-11-10 |
2014-04-28 |
주식회사 종근당 |
신규한 유전자 전달용 조성물
|
|
CA3018046A1
(en)
|
2011-12-16 |
2013-06-20 |
Moderna Therapeutics, Inc. |
Modified nucleoside, nucleotide, and nucleic acid compositions
|
|
WO2013106765A1
(en)
*
|
2012-01-13 |
2013-07-18 |
Genentech, Inc. |
Biological markers for identifying patients for treatment with vegf antagonists
|
|
DK2807188T3
(da)
|
2012-01-27 |
2019-10-07 |
Prothena Biosciences Ltd |
Humaniserede antistoffer, der genkender alpha-synuclein
|
|
WO2013116742A1
(en)
|
2012-02-01 |
2013-08-08 |
Mayo Foundation For Medical Education And Research |
Predicting responses to androgen deprivation therapy and methods for treating prostate cancer
|
|
US9254311B2
(en)
|
2012-04-02 |
2016-02-09 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of proteins
|
|
WO2014028487A1
(en)
|
2012-08-13 |
2014-02-20 |
Massachusetts Institute Of Technology |
Amine-containing lipidoids and uses thereof
|
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
|
CA2896058A1
(en)
|
2012-12-24 |
2014-07-03 |
Abbvie Inc. |
Prolactin receptor binding proteins and uses thereof
|
|
WO2014125291A1
(en)
|
2013-02-14 |
2014-08-21 |
Ucl Business Plc |
Agents which induce lymphangiogenesis for use in the treatment of cystic kidney disease
|
|
JP2016515120A
(ja)
|
2013-03-15 |
2016-05-26 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
抗アルファｖベータ５抗体を用いた急性腎損傷の治療及び予防
|
|
AU2014293670B2
(en)
|
2013-07-23 |
2019-08-01 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
|
CN112552401B
(zh)
|
2013-09-13 |
2023-08-25 |
广州百济神州生物制药有限公司 |
抗pd1抗体及其作为治疗剂与诊断剂的用途
|
|
WO2015095686A1
(en)
|
2013-12-20 |
2015-06-25 |
Trustees Of Boston University |
Assays and methods relating to the treatment of melanoma
|
|
US9209965B2
(en)
|
2014-01-14 |
2015-12-08 |
Microsemi Semiconductor Ulc |
Network interface with clock recovery module on line card
|
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
EA033604B1
(ru)
|
2014-01-31 |
2019-11-08 |
Boehringer Ingelheim Int |
Молекула анти-baff антитела, фармацевтическая композиция, содержащая эту молекулу, способы ее применения и кодирующий ее изолированный полинуклеотид
|
|
KR20160131082A
(ko)
|
2014-03-12 |
2016-11-15 |
프로테나 바이오사이언시즈 리미티드 |
Lg1-3에 특이적인 항-라미닌4 항체
|
|
EP3148564B1
(en)
|
2014-06-02 |
2020-01-08 |
Children's Medical Center Corporation |
Methods and compositions for immunomodulation
|
|
MA40513A
(fr)
|
2014-08-12 |
2017-06-21 |
Novartis Ag |
Conjugués médicament-anticorps anti-cdh6
|
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック， インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
|
CR20180097A
(es)
|
2015-07-14 |
2018-05-25 |
Immunext Inc |
Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
|
|
EP3464349A4
(en)
|
2016-05-23 |
2020-08-26 |
New York University |
COMPOSITIONS AND METHODS ASSOCIATED WITH ANTIBODIES TARGETING STAPHYLOCCAL LEUCOTOXINS
|
|
CA3045321A1
(en)
*
|
2016-11-30 |
2018-06-07 |
Atyr Pharma, Inc. |
Anti-hrs antibodies and combination therapies for treating cancers
|
|
EP3612567B1
(en)
|
2017-04-19 |
2024-09-11 |
Bluefin Biomedicine, Inc. |
Anti-vtcn1 antibodies and antibody drug conjugates
|
|
EP3694887A4
(en)
|
2017-10-13 |
2022-02-23 |
A & G Pharmaceutical, Inc. |
MONOCLONAL ANTIBODIES AND CONJUGATES TO PROSTAGLANDIN F2 RECEPTOR INHIBITOR AND USES THEREOF
|
|
KR102758204B1
(ko)
|
2017-10-30 |
2025-01-23 |
밀테니 비오텍 비.브이. & 씨오. 케이지 |
표적 세포의 선택적 형질도입을 위한 어댑터-기반 레트로바이러스 벡터 시스템
|
|
AU2019247511B2
(en)
|
2018-04-06 |
2025-10-16 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-NRP2 antibodies
|
|
KR20210148216A
(ko)
|
2019-04-01 |
2021-12-07 |
지앙수 헨그루이 메디슨 컴퍼니 리미티드 |
항-클라우딘 18.2 항체 및 이의 응용
|
|
WO2021058548A1
(en)
|
2019-09-23 |
2021-04-01 |
Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (F.S.P.) |
Antibodies for the diagnosis and/or treatment of atherosclerosis
|
|
CA3156803A1
(en)
|
2019-10-03 |
2021-04-08 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|
|
CN116075525A
(zh)
|
2020-03-31 |
2023-05-05 |
艾莱克特有限责任公司 |
抗mertk抗体及其使用方法
|
|
EP4418015A4
(en)
|
2021-10-15 |
2025-10-15 |
Shibaura Inst Tech |
IMAGE SENSOR DATA CONTROL SYSTEM
|
|
EP4423142A4
(en)
|
2021-10-27 |
2025-10-22 |
Atyr Pharma Inc |
COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2A ANTIBODIES
|
|
WO2023245117A2
(en)
|
2022-06-17 |
2023-12-21 |
Atyr Pharma, Inc. |
Compositions and methods comprising anti-nrp2 antibodies
|